Dr. John F Dipersio, M.D., Ph.D.

About John F Dipersio, M.D., Ph.D.

Education:

• Holds an MD (Doctor of Medicine).
• Earned a PhD (Doctor of Philosophy).

Experience:

• Since 2017, serves as the Director of the Center for Gene and Cellular Immunotherapy (CGCI) at Washington University School of Medicine, St. Louis, MO.
• From 2000 to 2022, was the Chief of the Division of Oncology at Washington University School of Medicine, St. Louis, MO.
• Has been a Professor of Medicine, Pediatrics, and Pathology/Immunology at Washington University School of Medicine, St. Louis, MO since 1997.
• Awarded the AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research in 2014.
• Received the Daniel P. Schuster Distinguished Translational Investigator Award from Washington University in 2013.

Area of expertise

Affiliated Hospitals

Washington University School Of Medicine

Washington University School Of Medicine- Siteman Cancer Center

Clinical Trials John F Dipersio, M.D., Ph.D. is currently running

CIML NK Cell Therapy

for Acute Myeloid Leukemia

This is a standard phase 2 study powered to demonstrate improvement in the 100 day leukemia free survival to 30% from \<10% expected with the use of reduced intensity haplo-HCT in this extremely high-risk patient cohort (based on the institutional experience using non-myeloablative / reduced intensity conditioning in a similar patient cohort). A formal safety evaluation will be done after every 6th patient enrolled and the trial will be stopped if noted to have unusually higher engraftment failure (acute GVHD rates (\>60% any grades or \>30% grade III/IV or ≥ 50% severe cGVHD) or engraftment failure rates (≥15%).

Recruiting1 award Phase 2

Duvelisib After CAR T-Cell Therapy

for Lymphoma

While chimeric antigen receptor T-cell (CAR T-cell) therapy produces impressive response rates in heavily pre-treated patients, early loss of response remains a barrier. One potential mechanism of relapse is limited CAR T-cell persistence. Pre-clinical research shows that PI3K inhibition represents an intriguing mechanism for increasing CAR T-cell persistence that is easily reversible and CAR T-cell agnostic. The investigators hypothesize that PI3K inhibition with duvelisib would be safe, may provide effective prophylaxis against cytokine release syndrome (CRS), and may enhance the persistence and efficacy of CAR T-cells in the treatment of hematologic malignancies.

Recruiting1 award Phase 1

More about John F Dipersio, M.D., Ph.D.

Other Doctors you might be interested in

Frequently asked questions